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Abstract
High‐risk human papillomavirus (HPV) genotypes infection associates with cervical
dysplasia and carcinogenesis. hr‐HPV transforming potential is based on E6 and E7 viral
oncoproteins actions on cellular proteins. A persistent infection with hr‐HPV leads to
progression from precursor lesions to invasive cervical cancer inducing changes in host
genome and epigenome. Pathogenesis and development of cancer associated with both
genetic and epigenetic defects alter transcriptional program. An important role for
malignant transformation in HPV‐induced cervical cancer is played by epigenetic changes
that occur in both viral and host genome. Furthermore, there are observations demon‐
strating that oncogenic viruses, once they integrated into host genome, become susceptible
to epigenetic alterations made by host machinery. Epigenetic regulation of viral gene
expression is an important factor in HPV‐associated disease. Gene expression control is
complex and involves epigenetic changes: DNA methylation, histone modification, and
non‐coding RNAs activity.  Persistent  infection with  hr‐HPV can cause  viral  DNA
integration  into  host  genome  attracting  defense  mechanisms  such  as  methylation
machinery. In this chapter, we aim to review HPV infection role in chromatin modification/
remodeling and the impact of HPV infection on non‐coding RNAs in cervix oncogene‐
sis. The reversible nature of epigenetic alterations provides new opportunities in the
development of therapeutic agents targeting epigenetic modification in oncogenesis.
Keywords: HPV, epigenetic regulation, DNA methylation, histone modification,
ncRNAs
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1. Introduction
Cervical cancer accounts for almost 12% of all cancers in women, representing the second most
frequent gynecological malignancy in the world, human papillomavirus (HPV) being consid‐
ered as etiologic agent of this malignancy [1, 2]. HPVs exhibit tropism for skin or mucosal
epithelium where they cause warts, benign lesions that usually regress. HPV prevalence is a
combination of incidental and persistent infections that have accumulated over time, due to lack
of clearance. Infection with a high‐risk HPV (hr‐HPV) type is considered necessary for the
development of cervical cancer, but by itself, it is not sufficient to cause cancer [3, 4].
The persistent infection with hr‐HPVs that have tropism for mucosal epithelia has been defined
as the cause of more than 98% of cervical carcinomas as well as a high proportion of other
cancers of the anogenital region (vulvar, vaginal, and penial) and oropharyngeal region [5]. It
is known that persistent infection with hr‐HPV genotypes is necessary but not sufficient for
the development of high‐grade cervical lesions and progression to malignancy. Persistent
infection is characterized by continuous detection of the virus or its intermittent detection, due
to latency, although the mechanism of latency has not yet been established but it is clear that
the differences between active and latent cervical infection are qualitative and/or quantitative.
The high prevalence of HPV infection in precancerous and cancerous cervical lesions confirms
its oncogenic potential, different genotypes seem to be responsible for invasive cancer
development. Approximately, 40 HPV genotypes were found to be associated with anogenital
infections and are generally classified according to their oncogenic potential into low‐, high‐,
and intermediate‐risk types. High‐risk or oncogenic types such as HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82 are considered so due to their presence in high‐grade squamous
intraepithelial lesions (HSIL) or cervical cancer [6]. hr‐HPV genotypes 16 and 18 are causing
more than 70% cervical cancer cases and most of the anogenital cancer as well as oropharyngeal
tumors in men and women.
The molecular mechanism of cellular transformation induction involves epigenetic abnormal‐
ities along with genetic alterations. HPV disrupts normal cell‐cycle control, promoting
uncontrolled cell division, and the accumulation of genetic damage. The transforming
properties of hr‐HPV E6 and E7 oncoproteins are in interaction with many host cell proteins
resulting in the maintenance and the reentering into cell cycle, permitting the virus to replicate,
as it is dependent on the host cell DNA replication machinery.
Both E6 and E7 oncoproteins are able to interfere with key cellular processes (cell cycle,
senescence, apoptosis and telomere shortening, differentiation). Furthermore, because of the
frequent integration of the hr‐HPV genome into a host cell chromosome, those two proteins
are the only viral proteins known to be consistently expressed in HPV‐associated cancers [7,
8]. Persistent infection with hr‐HPV genotypes determines progression from precursor lesions
to invasive cervical cancer by inducing changes in the host genome and epigenome. Tran‐
scriptional modification program through genetic and epigenetic alterations leads to cancer
development. Gene expression control is complex and involves epigenetic changes.
hr‐E6 protein is one of the most studied HPV proteins due to its many functions and is found
to be interacting with many host cell proteins. Although E6 protein leads to p53 protein loss,
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an important element of cell transformation [9], many studies have identified a number of
additional cellular targets that may play an important role. HPV E6 interferes with different
apoptosis pathways by additional interactions with key mediators (TNFR‐1, FADD, CASP8,
BAK, DFF40, GADD34/PP1, and TIP60) [10–15]. E6 protein is found to interact with proteins
involved in cell cycle, cell-cell contact and polarity (MUPPI, E6BP, MAGI 1/3, DLG, PAT,
paxillin, interacts with many proteins directly involved in DNA repair such as BRCA1, XRCC1,
and MGMT [16–24] and targets other cell proteins involved in chromosomal and DNA stability
for instance NFX1, hTERT, MCM7 [25, 26]. The E6 protein appears to have role in immune
evasion as it interacts with tyk‐2 and IRF‐3 proteins both of which are involved in interferon
signaling [27, 28].
E7 protein key activity is to overcome tumor suppressor block controlled by the pRb family
proteins (RB, p107, p130) through disruption of pRb–E2F complexes thereby initiating the E2F
mediated transcription [29]. E7‐pRB complex leads to functional inactivation and disruption
of cell‐cycle progression in S phase. Another E7 hr‐HPV function is as cell‐cycle regulator, in
doing so, the oncoprotein binds to p21/p27 and subsequent inactivates the CDK inhibitors [29,
30] and also to cyclins A, E in order to regulate cell cycle through pRb, p107 binding [31, 32].
On the other hand, E7 is known to be involved in transcription modulation by targeting host
cell proteins AP1, TBP, MPP2, E2F6, and Skip [33–37]. In addition, E7 hr‐HPV protein binds
to histone deacetylases (HDACs) in a pRb‐independent manner, which promotes cell growth.
The E7 protein can also associate, directly or indirectly, with histone acetyl transferases (HATs)
(p300, pCAF, and SRC1) and abrogates SRC1 associated HAT activity [38].
Following persistent infections with hr‐HPVs, E6, and E7 oncoproteins acts on the DNA and
cause epigenetic changes. The cooperation between genetic and epigenetic alterations leads to
the malignant phenotype and cancer progression. In contradiction to genetic alterations, the
epigenetic changes are reversible, making them therapeutic targets in various conditions, and
do not affect DNA sequence of the genes, but determine the gene expression regulation acting
on the genome. It is well supported that cancers are epigenetically deregulated. Disruption of
epigenetic processes determines altered gene function leading to imprinting disorders,
developmental abnormalities and cancer. Epigenetic regulation of viral gene expression is an
important factor in HPV associated diseases, due to processes that arise independently of
changes in the underlying DNA sequence. Gene expression control is complex and involves
epigenetic changes such as DNA methylation [39], histone modifications, and chromatin‐
remodeling proteins [40] and DNA silencing by non‐coding RNAs (ncRNAs) [41].
Taking into account that molecular mechanism induction of cellular transformation involves
epigenetic abnormalities along with genetic alterations, in this chapter, we aim to review: (1)
DNA methylation and cervical cancer; (2) the role of HPV infection in chromatin modification/
remodeling; (3) the impact of HPV infection on ncRNA in cervix oncogenesis; (4) epigenetic
changes involved in viral gene expression; (5) potential epigenetic biomarkers in cervical
cancer.
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2. DNA methylation and cervical cancer
The most studied epigenetic mechanism is DNA methylation. DNA methylation is a general
term for processes of DNA bases (adenine, cytosine, and guanine) change by addition of a
methyl group. Methylation of DNA bases can be achieved either under physiological condi‐
tions after a specific endogenous enzyme reaction by transferring the methyl group from a
donor (biological methylation), or non‐physiological conditions through the action of chemical
compounds: alkylating agents. DNA methylation plays an important role in various cellular
processes including gene expression, silencing of transposable elements, as well as in the
defense mechanism against viral infection.
In several types of cancer, many genes have been reported to be hypermethylated. DNA
hypermethylation results in blocking of affected gene transcription, causing silencing them.
In cancer, hypermethylation is considered one of the most important mechanisms for tumor
suppressor gene silencing, responsible for the control of the normal cellular differentiation
and/or inhibition of cell growth. The main chemical DNA modification is methylation of
cytosine, commonly found in areas with CpG dinucleotides islands. Almost 60% of promoters
of genes encoding proteins in the human genome contain CpG islands, and the majority are
methylated in varying degrees, depending on the tissue [42].
Cytosine methylation is a stable inherited and reversible hallmark and is generally associated
with transcriptional repression. The methylation inhibits transcription factors that bind to
recognized DNA sequences by the recruitment of methyl cytosine binding protein (MECP and
MBD) with corepressor molecules. The way that 5‐methylcytosine (5‐mC) repress transcription
at the promoter level is by the recruitment of methyl binding proteins (MeCP2, MBD1, MBD2,
MBD3, MBD4), which subsequently interacts with another protein to repress DNA transcrip‐
tion as well as HDAC and other chromatin remodeling enzymes [43].
DNA methylation is controlled by DNA methyltransferase (DNMT), which catalyses the
transfer of the methyl group from S‐adenosyl methionine donor (SAM). Three active catalytic
DNA methyltransferases were identified as follows: DNMT1, DNMT3A, and DNMT3B.
First tumor suppressor gene identified as hypermethylated was pRB, and then was followed
by multiple publications describing similar phenomena for a variety of tumor suppressor
genes such as p16, MLH1, VHL, and E‐cadherin [44, 45]. It remains controversial whether
tumor suppressor gene hypermethylation is a cause or a consequence of silencing them. DNA
methylation is reversible and various chemical compounds are known that can reactivate gene
expression [46].
On the other hand, DNA hypermethylation may be a secondary process, due to changes in
chromatin role in maintaining the status repression of gene expression. More evidence of this
hypothesis, resulting from experiments showing that when DNA methyltransferase expres‐
sion was blocked in vitro, histone H3K9 methylation determined silencing of p16 gene in the
absence of promoter DNA methylation [47, 48]. It was shown in cervical carcinoma that tumor
suppressor genes are silent or abnormal diminished expressed due promoter hypermethyla‐
tion (Table 1).
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On the other hand, microRNA genes undergo methylation‐mediated transcriptional repres‐
sion in cervical cancer miR‐149, miR‐375, miR‐432, miR‐1286, miR‐641, miR‐1290, miR‐1287,
and miR‐95 [75–77].
CADM1, MAL, PAX1, and ADCYAP1 genes promoter hypermethylation were found to be
involved in HPV‐mediated transformation and may be significantly associated with the
development of cervical cancer [78].
It was shown that hTERT, mir124‐2, and PRDM14 were the first genes that became methylated
during experimental immortalization. Following immortalization, ROBO3 methylation and
CYGB was methylated, followed by CADM1, FAM19A4, MAL, PHACTR3, and SFRP2 [79].
3. The role of HPV infection in chromatin modification/remodeling
Nucleosomes are the basic repetitive units of chromatin and are intended to pack huge
eukaryotic genome in the nucleus (mammalian cells contain approximately 2 m linear DNA
packed into a nucleus‐sized 10 mm diameter). Nucleosomes are further compacted to form
chromosomes. These structures confer DNA compaction, but also create a base for the gene
expression regulation. Nucleosome core particle is approximately 147 base pairs wrapped
around a histone octamer made up of two copies of the histones H2A, H2B, H3, and H4.
Gene Methylation percentage Activity
DcR1/DcR2 100% Apoptosis [50–53]
hTERT 57%
p16 8–42% Cell cycle control [54, 55]
p73 39%
PTEN 58% WNT pathway [56, 57]
E‐cadherin 28–80.5%
APC 11–94%
MGMT 5–81% DNA repair [58]
FANCF 30% FA‐BRAC pathway [59, 60]
BRACI 6.1%
hMLH1 5% DNA mismatch repair [61]
RASSF1A 0–45% Ras negative effector [62]
DAPK 45–100% Cell death/metastasis [63]
TSCLC1 58–65% Tumor suppressor [64]
FHIT 11–88% Cell death/repair [65, 66]
HIC1 18–45% Transcriptional factor [55, 67]
RARβ 33–66% Cell differentiation [68, 69]
TIMP2/TIMP3 47% Metalloprotease inhibitors [70, 71]
Calveolina1 6% Calveole membrane [72, 73]
ERα 25% Estrogen receptor alpha [74]
miR124 59% Tumor suppressor [75]
miR‐34b 48%
miR‐203 57%
Table 1. Hypermethylated tumor suppressor genes in invasive[R1] cervical cancer (Adapted with permission from
Dueñas‐González et al. [49]).
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Histone H1 (linker histone) and its isoforms are involved in chromatin compaction and
underlying nucleosomes condensation. Compaction of chromatin in the cell nucleus is
necessary but is not fully understood. In nucleosomes compacting DNA linker—10 nm has an
important role. A chain of nucleosomes can be arranged in 30 nm chromatin fibers whose
formation is dependent of histone H1. A 30‐nm chromatin fiber is arranged as a loop around
a central protein scaffold to generate the active form of the transcription‐euchromatin.
Compacting the fibers can lead to transcriptionally inactive form—heterochromatin [80].
3.1. Histone modifications
Covalent modifications of histones (epigenetic changes) are regulatory elements important in
many biological processes. They affect chromatin interactions by structural changes in the
histones or by modifying the electrostatic interactions and non‐histone proteins recruit [81].
Histones can undergo a variety of post‐translational modifications at the N‐terminus, which
is represented by acetylation, methylation, phosphorylation, sumoylation, ADP–ribosylation,
and ubiquitination. They can alter the DNA histone interaction, with a major impact on
chromatin structure. Some covalent modifications of histones are involved in transcription and
are associated with DNA repair process. On the other hand, the phosphorylation of histone
H2AX appears to be unique modification in DNA repair. Histone modifications may influence
both among themselves and in interaction with methylated DNA, and the presence of
numerous changes in the combined space‐time context creates a program of genome expres‐
sion profile specific to each cell to keep identity.
3.2. Histone acetylation
Histone acetylation is a modification of the lysine aminoacid that neutralizes the positive
charges occurring at specific targets of nucleosome core. It has been speculated that histone
acetylation can alter DNA interaction, helping to create more open chromatin architecture.
Acetylation of lysine residues is catalyzed by HATs by transfer of an acetyl group from acetyl‐
coenzyme A to ε nitrogen of the lysine aminoacid. With few exceptions, these changes tend to
create a relaxed form of chromatin, open for transcription, while deacetylation performed by
HDACs is associated with transcriptional repression. Many transcriptional activators have
been identified possessing intrinsic activity acetyl transferase: Gcn5/PCAF, CBP/p300, and
SRC‐1. Similar to these co‐activators that exhibit HAT activity, there are co‐repressors with
HDAC activity, such as mSin3a, NcoR/SMRT and NURD/Mi‐2 [82]. Rpd3 complex is an
exception, being a complex with HDAC activity, associated with the active form of RNA
polymerase II. Through this association is Rpd3 complex transcriptional repressor of initiation
[83].
3.3. Histone methylation
Methylation of H3 and H4 histone at lysine and arginine residues arises in mono‐, di‐, or tri‐
methylated form and is conducted using a specific histone methyltransferase (HMT) that acts
at the level of these residues. HMTs can catalyze the addition of up to three methyl groups on
the ε nitrogen of lysine [84]. Co‐activators, such as arginine methyltransferase (CARM1) and
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protein arginine methyltransferase (PRMT1), are essential for histone H3 and H4 arginine
methylation [85]. Most of HMTs contain catalytic domains, named SET conserved domains
named after D. melanogaster Su (var)3‐9 Enhancer of Z‐(E(z)) and trithorax (TRX), although
there are some exceptions of HMTs without SET domain [85–88]. H3K4 and H3K36 methyla‐
tion is carried out by several methyltransferases. This redundancy makes the study of histone
methylation more complex. Mammalian H3K79 methyltransferases include Suv39h1,2, G9a,
and ESET [89]. EZH2 catalyses methylation of histone H3K27 and PR‐Set2 (also known SET 8)
with Suv4‐20h1,2 catalyzes histone H4K20 methylation [90]. Methylation of H3K9, H3K27, and
H4K20 is generally linked to the formation of heterochromatin in the presence of a transcrip‐
tional repressor HP1, while methylation of H3K4 and H3K36 is associated with transcription‐
ally active regions [91]. Methylation of histones lysine is reversible, being made by two
enzymes families: aminooxidases (LSD1) and hydroxylases (JmjC family members), which
may also demethylate trimethylated lysine [92, 93]. It was identified a series of proteins that
bind to post‐translationally modified histones. For example, methylated lysine residues can
bind to protein with conserved regions, like plant‐homeodomain (PHD) and chromodomain
(CHD), whereas acetylated lysine residues bind to proteins with bromodomain [94]. These
recruitment and recognition events can serve as a regulatory mechanism for other mechanisms
that lead to other modifications of the histones. Two main complexes were identified, accom‐
panying epigenetic changes, and containing members of trithorax (TrxG) and Polycomb (PCG)
group. Some components of complex PCG and TrxG exhibit histone–methyltransferase
activity, while other members interpret histones modifications playing a central role in gene
regulation, coordinating such DNA availability for development and to establish cell faith.
This are accomplished by pausing the state of balance between silent transcriptionally
heterochromatin (PCG) and competent transcriptionally euchromatin (TrxG) [95].
3.4. Histone phosphorylation
Histones are phosphorylated at specific sites (serine residues) during cell division [96].
Phosphorylation process requires certain kinases. All four histone suffer phosphorylation;
their biological meanings depend on the context. For example, histone H4S1 is evolutionary
conserved role in chromatin compaction during the late stages of gametogenesis [97]. Phos‐
phorylation of histone H2A (human—Ser14 in yeast—Ser10) is correlated with meiotic
chromosome condensation, but disappears during meiotic division [98]. Chromatin conden‐
sation in apoptosis has been linked to the phosphorylation of histone H2B, in both humans
and yeast. Histone phosphorylation seems to have a role in transcription. It was shown that
phosphorylation of histone H3 determines the competence of transcriptional response for JUN
and FOS genes immediately. These changes occur due to activation of Ras‐MAP kinase
pathway by growth factors.
3.5. Histone ubiquitination
Ubiquitin is a polypeptide that is attached covalently to other proteins as a result of a steps
series involving activation and conjugation enzymes of ubiquitin E1 (ubiquitin activating
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enzyme), E2 (ubiquitin conjugating enzyme) and ubiquitin ligase (E3) [99]. Polyubiquitination
or more ubiquitin molecules addition to a protein is a classic signal for degradation via the
proteasome. Histone H2A was first protein identified to serve as ubiquitin substrate [100].
Histone ubiquitination may be reversible using deubiquitinases. Like histone acetylation,
ubiquitination is important in regulating gene expression. Highly ubiquitinated histones H2A
and H2B have been associated with transcriptionally active sequences. Removing the ubiquitin
residues on histone H2A leads to transcriptional repression [101].
3.6. ADP‐ribosylation
ADP‐ribosylation is a post‐translational modification of proteins, including histones, which
involves the addition of one or more residues of ADP and ribose. Mono or poly ADP-ribosy‐
lation is mediated by MARTs (Mono-ADP-ribosyltransferases) or PARPs (poly-ADP-ribose
polymerases) enzymes [102]. ADP‐ribosylation of histones is carried out in a single‐site
H2BE2ar1 [103]. Recently it was demonstrated the role of PARP‐1 in transcriptional activity,
but only if that DNA repair process was induced [104].
3.7. Crosstalk between DNA methylation and histone modifications
Several studies have shown that the relationship between DNA methylation and histone
modifications is mediated by a group of proteins whose function is the binding to methyl
groups from DNA, including proteins which bind to CpG methylated islands (MeCP2),
proteins with binding domain to CpG methylated islands (methyl‐CpG binding domain
protein 1, MBD1), and Kaiso protein‐also known as ZBTB 33 (Zinc finger and BTB domain
containing protein 33). These proteins are localized to the methylated promoters and recruit a
protein complex containing HDACs and HMTs [105–107]. These studies suggest that DNA
methylation may induce structural changes to the chromatin by altering the histone modifi‐
cations. It is also known that DNA methylation inhibits methylation of histone H3K4me [108,
109]. In embryonic stem cells gene, Oct3/4 is inactivated after the fate is determined to a
particular cell type. The silencing process is realized by recruiting a co‐repressor complex
consisting of G9a methyltransferase and with HDAC enzyme activity. DNMT3A and
DNMT3B DNA methyltransferases are subsequently recruited, catalysing the de novo DNA
methylation at the gene promoter level [110]. Interaction between G9a protein and DNA
methyltransferases (DNMT3A and DNMT3B) depends on the ankyrin motif of G9a protein
[111]. In exchange, the SET domain responsible for methyl transferase activity of the G9a
protein does not interact with DNA methyltransferases [112, 113]. These data suggest that
DNA methylation at the promoter level depends on recruiting especially G9a protein and less
of its methyltransferase activity. Interaction between histone H3K9 methylation and DNA
methylation represents a model in which these two changes determine a strong silencing loop
or bidirectional interference.
Recently, it was established with the aid ChIP and bioinformatics a link between methylation‐
mediated by PCG on histone H3K27 and de novo DNA methylation in cancers, which claims
that the signal required by PRC2 during development predisposing certain genes to de novo
methylation later [113–115]. In tumor cells were observed interactions between DNA methyl‐
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ation and histone H3K9 methylated, thereby contributing to a stable silencing mechanism.
PCG and EZH2 proteins are members of Polycomb repressor complex 2 (PRC2) which has
methyltransferase activity with substrate specificity for histone H3K27. Histone H3K27me3
serves as specific binding signal to a chromodomain of another Polycomb repressor complex
(PRC1). PRC1 blocks transcriptional factors recruitment, therefore the presence of PRC1 stops
transcription initiation.
Biochemical studies have also shown that DNA methyltransferase binds EZH2 to certain
conditions [115–117]. Histone H3K9 and H3K27 methylation presence does not always lead to
the de novo DNA methylation. A subset of target genes for complex PCG can be methylated in
cancer. Additional factors are required for DNA methylation in genes showing changes in the
histones. Recently, it has been shown that the histone H3K27 trimethylation is PCG mediated
and is a mechanism that determines tumor suppressor gene silencing in cancer, which is
independent of promoter methylation [118, 119]. This lack of dependence between DNA
methylation and histone modifications of these studies demonstrated conflicting results of
previous studies. It should be noted that most of the genes presenting at their level histone
H3K27me3 in prostate cancer do not show islands CpG motifs in the promoter, instead gene
targeted by PCG complexes show generally the CpG promoters islands in embryonic stem
cells ES [120]. This indicates that the histone H3K27 methylation processes mediated by the
PCG complex in ES, normal and tumor cells are different because the tumor cells by removing
the functional path of histone H3K27me3 usurps silencing mechanisms. Therefore, it was
established the existence of 3 directions involved in silencing machinery associated H3K27
methylated histone mediated by PCG complex. The first relates to de novo repressed genes by
methylation of histone H3K27, PCG mediated, and targets certain gene in particular which do
not present CpG islands at promoter level. The second direction supports that during onco‐
genesis an early gene subset became methylated and CpG islands of the promoters are initially
marked by PCG complex. This includes also those genes which undergo epigenetic reprog‐
ramming and are silent initially by the PCG and then suffer DNA methylation process like an
alternated silencing mechanism. This epigenetic silencing switch through DNA methylation
reduces epigenetic plasticity, blocking key regulators and contributes to tumourigenesis
[121]. Third mechanism supports the fact that DNA methylation and histone H3K27me3 co‐
exist at the same promoter and methylation H3K27me3 histone by PCG silencing machinery
is dominant. The silencing machinery may contribute to oncogenesis process in various forms,
which can constitute in a repressor mechanism from flexible to plastic up to stable inactivation
maintained by DNA methylation.
3.8. Chromatin and cancer
The involvement of DNA methylation process and chromatin changes in oncogenesis is
indisputable, but separation of the genetic from epigenetic events is artificial. New evidence
has shown that primary genetic defects (mutations in the genes coding for the receptors of
growth factors, adhesion molecules, the gene that affects the DNA methylation and histone
modifications as DNMT, HAT, or HDAC) lead to altered DNA methylation and changes in
chromatin pattern. Both the endogenous and exogenous carcinogens do not cause genetic
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mutations but first epigenetic alterations, which highlights that epigenetic alteration is a step
in oncogenesis.
All classical genetic alterations as mutations in tumor suppressor genes and in oncogenes can
affect gene transcription (e.g., mutations in Ras gene, HER2 gene amplification). It is not
surprising that the control of gene transcription machinery can be directly involved in
oncogenesis. Although the complex nature of transcriptional regulation is uncertain, balance
disruption of enzymatic activity responsible for maintaining acetylated histones status is
expected to occur in cancer. p300/CBP histone acethyltransferase gene exhibits mutations in
various cancer type (lung tumors, esophageal, ovarian, and gastric) [122–125]. Chromosomal
translocations that targeted CBP/p300 gene locus affects transcription by their merger the
translocated fragment with genes located in the chromatid area where they were joined (event
met in hematological cancers such as acute myeloid leukemia) [126, 127].
Limited data regarding the global profile of histone modifications in oncogenesis can be found,
but as a highlight is the overall loss of H4K16 monoacetylation and H4K20 trimethylation
[128]. It has also been found that an important role in tumourigenesis is represented by changes
of histone from promoters of tumor suppressor genes that determine their silencing. Such
modifications are the loss of histone H3K9 acetylation and di/trimethylation of H3K4, H3K9
dimethylation, or trimethylation of H3K27 [129]. Several studies have reported a high level of
EZH2 expression, which promotes tumor growth in both in vitro and in vivo, as identified in a
number of human cancers such as melanoma, leukemia, prostate, and breast cancer [130,
131]. It has been shown that EZH2 could be a potential biomarker, and its expression was
correlated with aberrant H3K27 trimethylation and silencing of tumor‐suppressor genes [119,
132].
Another frequent mechanism in cancer is the inactivation H3K27 demethylase‐UTX/KDM6A
(lysine (K)‐specific demethylase 6A). KDM6A gene mutations have been reported in many types
of tumors: multiple myeloma, esophageal squamous cell carcinoma, and renal cell carcinoma
[133].
3.9. Alteration of histones changes in cervical cancer
Histone modifications and alterations have recently begun to be studied in the cervical cancer.
Analysis of histone modifications in the progression of cervical lesions is relatively at the
beginning, there are few studies which indicate an association between alterations of histones
and cervical cancer development. There are some data supporting that chromatin pattern in
cervical samples may help in cervical neoplasia diagnosis, particularly for glandular lesions.
The molecular basis of chromatin modifications is not fully determined [134]. E6 and E7 viral
oncogenes expression is essential but not sufficient for neoplastic transformation, many studies
highlight the important role of epigenetic changes in cervical carcinogenesis. Recently, it has
been shown that E6 and E7 oncoproteins interacts with histone‐modulating enzyme, which
regulates transcription via the host cell chromatin [84]. A recent report showed that in
tumourigenesis, tumor cells lose monoacethylated and trimethylated histone H4 (acetylated
Lys16 and trimethylated Lys20) form, that being associated with hypomethylation of repetitive
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DNA sequences [135]. Huang et al. [136] showed that the expression levels of HDACs were
found to be increased in cervical dysplasia and invasive carcinoma.
It was reported that MGMT a DNA repair protein silencing seems to be associated with a
reduction in acetylated histones [137]. Moreover, the activation of Wnt signaling pathway may
be realized by a transcriptionally repressed Wnt antagonist DICKKOPF‐1 (DKK‐1), by histone
deacetylation in HPV‐infected cervical cells [138]. HDAC function is necessary for HIF‐1
(hypoxia inducible factor‐1) activity, and it was found that E7HPV protein can block the
interaction of HDACs with HIF‐1α, activating HIF‐1‐dependent transcription for a range of
pro‐angiogenic factors [139, 140]. Silencing of proliferation repressor protein osteo‐protegerin
(OPG) and retinoic acid receptor β2 (RAR‐β2) was found to occur through histone modification
as well as DNA methylation [141, 142].
It has been shown that phosphorylated and acetylated forms of histone H3 in cervical swabs
are associated with progression from CIN I to CIN II and CIN III [143]. The balance between
HDACs and HATs activity has a key role in regulating gene transcription [144]. This balance
must be maintained in normal cells, to prevent an uncontrolled proliferation and cell death.
E6 and E7 HPV target numerous cellular proteins to disrupt cell growth and proliferation,
including HDACs and HATs. E7 hr‐HPV protein binds to HDACs, this interaction being
performed by Mi2β, a member of the nucleosomes remodeling complex and acetylation of
histones (NuRD), which possess the ability to modify chromatin structure by both the
deacetylation of histones and by the repositioning ATP‐dependent nucleosomes [145]. The
interaction the E7‐HDACs is independent of binding to Rb protein and E7 gene mutations
abolish its ability to target the HDACs and to transform mouse fibroblasts [84]. E6 hr‐HPV
protein shares with other DNA tumorigenic viruses’ ability to target CBP/p300. The interaction
involves C‐terminus zinc finger of E6 protein and 1808–1826 residues of CBP; as a result, the
p53 transcriptional activity is reduced, independently of p53 protein removal through the
proteasome degradation pathway [146]. E7, E6 protein binds to the transcriptional co‐activator
p300/CBP, being a crucial step in cellular transformation [147].
Histone methylation is acknowledged to be a dynamically process controlled by two types of
enzymes that work together to maintain global histone methylation patterns: HMTs and
histone lysine demethylases (KDMs) [42, 95]. Histone methylation can occur at different lysine
residues. The interaction between HMTs and KDMs locally adjusts the degree of methylation
which results in the activation or repression of gene expression, depending on the specific
target lysine residue [95]. Thus, the degree of methylation and the position of methylated lysine
have different consequences: overall methylation of H3K9 (histone 3 lysine at position 9),
H3K27 (histone 3 lysine at position 27), and H4K20 (histone 4 lysine at position 20) is linked
to the heterochromatin formation in the presence of a transcriptional repressor associated with
HP1, while the methylation of H3K4 (histone 3 lysine in position 4) and H3K36 (histone 3 lysine
in position 4) is associated with transcriptionally active regions [148–152]. Generally, methy‐
lated H3K4, H3K36, and H3K79 are considered activating marks, whereas methylation of
H3K9, H3K27, and H4K20 are often associated with gene silencing [150–154].
E6, E7 oncoproteins can associate with enzymes that modulate histone acetylation, and thus,
regulate the transcriptional capacity of host cell chromatin [151, 152, 155, 156]. Especially,
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KDMs expression was found to be deregulated and associated with cancer aggressiveness.
KDMs were further proposed as potential tumor biomarkers and could play distinct role in
cancer progression acting either as putative oncogene or tumor suppressor based on different
transcriptional role (gene activation/repression) [157, 158].
McLaughlin‐Drubin et al. [159] sustain that E7 HPV16 can induce epigenetic and transcrip‐
tional alterations by transcriptional induction of the KDM6A and KDM6B histone 3 lysine 27
(H3K27)‐specific demethylases.
KDM5C demethylase role in the pathogenesis of HPV‐induced has been described in the
literature. KDM5C is recruited by the E2 viral protein for E6 and E7 oncogenes transcriptional
repression through the LCR region of HPV. The results obtained indicate KDM5C as a good
marker for severe lesions and SCC [160].
Another recent study showed that KDM4C, KDM5C, KDM6A, and KDM6B genes expression
significantly increase in high‐grade lesions (CIN 2+) and SCC presenting a positive correlation
with HPV infection. A significantly increased of KDM4C expression levels in SCC samples
compared with precancerous lesions propose it as a suitable tumor marker. KDM4C/GASC1/
JMJD2C/ is a histone demethylase that is mainly regarded as oncogene due to its role in
demethylating heterochromatic H3K9me3/2 [161]. Another good marker for high‐risk lesions
and SCC seems to be KDM5C whose expression levels were found increased in CIN2+ lesions
and significantly increased in SCC cases [160, 161].
p16 gene expression in normal cells is generally low due to gene silencing by H3K27 trime‐
thylation and PRC complex action. It was observed that the E7 oncogene expression may
reduce residues H3K27 required for repression of PRC1 complex, leading to transcriptional
activation of histone H3K27, histone demethylases KDM6A, and KDM6B through an unknown
mechanism. In response to the stimulation of the RAS/RAF transcriptional activation of
KDM6B occurs possible via AP1, leading to the removal of H3K27me3 (histone 3 lysine at
position 27 trimethylated) residues and increasing expression of p16INK4a [162]
The literature data suggest an important role as biomarker for p16INK4a tumor‐suppressor
gene in HPV‐induced lesions and cervical cancers. The mechanism of induction of p16
expression by the E7 viral oncogene is believed to be achieved by the activation of E2F
transcription factor [163]. Later it was observed that from the p16 promoter are missing
response elements to E2F and E7 HPV16 mutated variants that are defective in binding/
degradation of pRb and E2F transcription are not activated; p16 expression can be induced by
the wild‐type and variants [159]. p16INK4 expression is induced by demethylation of H3K27
residues KDM6B mediated, that underpins the induction of senescence by oncogenes
(Oncogene induced senescence—OIS), an intrinsic cellular innate tumor suppressor mechanism
triggered by oncogenes such as RAS [164]. E7 oncogene causes degradation of pRB, the main
mediator of halting cell growth and senescence induced by p16, repealing the mechanism of
induction of senescence by oncogenes. The mechanism of inactivation of pRB by E7 can be
explained by the necessity to avoid eliminating E7 HPV positive cells targeted by OIS. Such
high levels of p16 observed in this study correlated with an increased expression of KDM6B
histone demethylase due to E7 oncogene activity on H3K27 modulators.
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4. The impact of HPV infection on ncRNA in cervix oncogenesis
In the latest years, thanks to a growing number of studies focusing on high‐throughput next
generation sequencing (NGS), large‐scale genome, and genome‐wide transcriptome methods,
a new world of RNA molecules: ncRNAs have emerged [165].
More recently, through deep sequencing data obtained by transcriptome projects such as
ENCODE (Encyclopedia of DNA Elements Consortium), it has been revealed that around 90%
of genomic DNA in eukaryotes is transcribed with just 1–2% of the transcript encoding for
proteins, the vast majority being transcribed as ncRNAs [166].
Some of the ncRNAs molecules appear to be important players in genome functioning acting
as “regulatory RNAs”. Experimentally data gathered so far sustain the ncRNAs involvement
in many biological processes; they seem to have important roles in genes transcriptional and
posttranscriptional regulation, RNA splicing, translation and turnover, also in epigenetic
modifications [167, 168].
Furthermore, given the regulatory role that these non‐coding molecules possess in normal
biological processes, it has been presumed that they might play a significant role also in
different types of pathologies. There are accumulating evidence highlighting a major role for
these molecules in various diseases where they appear to have aberrant expression and
contributes to disease development and progression.
Several studies showed ncRNAs involvement in diseases such as neurodegenerative, cardio‐
vascular, immune diseases and in neoplastic transformation [169]. Regulatory ncRNAs could
be classified according to their length in three categories [170]:
• Small ncRNAs (approximately 18–31 nucleotides) which comprises: small interfering RNAs
(siRNAs), microRNAs (miRNAs), PIWI‐interacting RNAs (piRNAs).
• Medium ncRNAs (31–200 nucleotides): promoter‐associated small RNAs (PASRs), termi‐
nal‐associated small RNAs (TASRs), transcription initiation (tiRNAs).
• Long ncRNAs (lncRNAs) (>200 nucleotides in length) that includes: long intergenic ncRNAs
(lincRNAs), pseudogenes, sense and antisense RNA, enhancer RNAs (eRNAs).
miRNAs molecules are approximately 18–24 nucleotides in length, ncRNAs that regulate
genes expression in eukaryotic organisms. These RNA molecules are known to be a part of
RISC complex (RNA‐induced silencing complex) and are involved in gene silencing by pairing
with complementary sequences at 3' UTR (untranslated regions) or coding region of a target
messenger RNAs (mRNAs) that leads to mRNA degradation and blocking protein synthesis
[171–173].
Through this interaction miRNAs molecules play an important role in specific cellular
processes including cellular development, proliferation, differentiation, apoptosis, and
thereby controlling the expression level of hundreds important genes involved in these
processes [174, 175].
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Numerous studies have reported miRNAs aberrant expression profiles in different types of
cancer. Until recently, the most extensively studied ncRNAs in oncogenesis, miRNAs appear
to have a dual nature in neoplastic transformation acting either as tumor suppressors and/or
as oncogenes depending on the cellular context [176].
miRNAs known to have oncogenic functions also called “oncomiRs” have frequently been
demonstrated to control processes such as cell differentiation, apoptosis, and tumor develop‐
ment through tumor suppressor genes inhibition. Several examples of well‐known oncomiRs
linked to malignant transformation are miR‐15, miR‐16 found upregulated in many types of
leukemia's and lymphomas [177, 178]; miR‐155 overexpressed in chronic lymphocytic
leukemia (CLL), B‐cell lymphoma, anaplastic large cell lymphoma (ALCL), Hodgkin's or
Burkitt's lymphoma and in breast tumors [179–182]; miRNA‐17‐92 cluster (oncomiR‐1)
deregulated in multiple types of cancer: lung (particularly in small‐cell lung cancer and
aggressive forms), pancreatic, hepatocellular, colorectal, breast, ovarian, and hematopoietic
cancers [183, 184]; meanwhile, miR‐106a has an oncogenic role in pancreatic, colon cancer, and
T‐cell lymphoma [185–187]; another promising oncomiR is miR‐21 found overexpressed in
various cancers including breast cancer, lung cancer, colorectal cancer, hepatocellular carci‐
noma, glioblastoma [188–196].
On the other hand, in cancer, it was shown that some miRNAs are consistently downregulated
and act as tumor suppressor with example such as: miR‐15a and miR‐16 cluster that is often
deleted or downregulated in tumor cells [197–200] or miR‐34 family members that were
identified as potential tumor suppressor in many cancers [201–203], also miR‐124 was found
significantly downregulated in several types of human cancers [203–206]; miR‐122 demon‐
strated to regulate intrahepatic metastasis in hepatocellular carcinoma and thus acting as a
tumor suppressor for this pathology [207] and mir‐203 was shown to suppress cell proliferation
and migration in various types of cancer [208–210].
A malignancy where miRNAs role has been extensively investigated is cervical cancer. There
are many reports that emphasize a substantial role for these non‐coding molecules in cervical
oncogenesis.
An interesting research direction in miRNAs field is their relationships with viral infections.
Various studies support the fact that some cellular miRNAs expression can be regulated by
virus infection and these observations are not surprising given the host defense mechanisms
against pathogen agents such as bacteria and viruses.
Researchers also have identified several cellular miRNAs whose levels can be modulated by
HPV infection, respectively, by viral E6 or E7 oncoprotein of high‐risk genotypes [211].
Studies based on miRNAs expression profiles revealed a differentially pattern of expression
in cervical tumors tissue compared with normal tissue, still due to different detection methods
and experimental systems use in some cases the observations are contradictory (Table 2).
Recently based on the observation that some viruses could express their own set of miRNAs,
there is an ongoing effort to identifying these miRNAs and to establish their role during viral
infection. Reports revealed that miRNAs encoded by viruses target host genes involved cell
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proliferation, apoptosis, host immunity regulation, in order to maintain their survival and to
escape from immune system response.
Over 200 miRNAs encoded by several virus families have been identified to date, many of
them being found for herpes viruses and Epstein–Barr virus (EBV) [237]. For instance, it was
found that EBV encodes more than 40 miRNAs that presents different expression levels during
viral infection and some are involved in maintaining viral latency [238, 239]. From our
knowledge to date, there are no reports on the existence of HPV‐encoded microRNAs.
Although researcher's attention in latest years was mainly focus on short ncRNAs molecules
and their functions in normal/pathological conditions, at present great efforts are put into
investigating the major part of the non‐coding transcriptome namely lncRNAs transcripts.
It has been revealed that certain lncRNAs can control gene expression through a range of
different mechanism including transcriptional, splicing, and post‐transcriptional regulation
or at epigenetic levels by chromatin remodeling and histone modification regulation [240–242].
Even though few lncRNAs have been well characterized, from the knowledge accumulated so
far it is clear that they represent significant gene regulators and play critical roles in many
miRNA Expression pattern miRNA detection method References
‐21 High Microarray, Northern blot, qRT‐PCR [212–214]
‐27a High qRT‐PCR [214]
‐34a High qRT‐PCR [214, 215]
‐155 High Microarray, Northern blot, qRT‐PCR [214, 216, 217]
‐146a High Microarray, Northern blot [216]
‐125 High qRT‐PCR [215]
‐196a High qRT‐PCR [214, 218, 219]
‐203 High qRT‐PCR [214, 220, 221]
‐138 High qRT‐PCR [222]
‐7 High qRT‐PCR [221]
‐20a High qRT‐PCR [220, 223]
‐221 High qRT‐PCR [214, 224]
‐200 High qRT‐PCR [225]
‐93 High qRT‐PCR [225]
‐124 Low qRT‐PCR [226, 227]
‐143 Low Microarray, Northern blot, qRT‐PCR [216, 228]
‐145 Low Microarray, Northern blot [216, 229]
‐149 Low [212]
‐195 Low Microarray [230]
‐34a Low qRT‐PCR, Northern blot [231, 232]
‐214 Low Northern blot, qRT‐PCR [233]
‐23b Low Microarray
qRT‐PCR [212, 234]
‐519 Low Northern blot, qRT‐PCR [235]
‐218 Low Northern blot, qRT‐PCR [236]
‐372 Low qRT‐PCR [237]
Table 2. Examples of miRNAs aberrant expressed in cervical cancer.
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cellular and development processes. Therefore, taken into account, the wide functions that
lncRNAs hold, it is not surprising that their alterations are associated with an extensive range
of disease.
Several studies have reported lncRNAs involvement in cardiovascular diseases, neurological
disorders, immune disease, and also in cancer, data indicates a differential lncRNAs expression
in many types of malignancy including, breast cancer, colon cancer, prostate cancer, hepato‐
cellular carcinoma, pancreatic cancer, lymphomas [243].
Currently, the expression profile of various ncRNAs has become an important feature of
oncogenesis process. There are numerous publications indicating an association between
lncRNAs expression and malignant transformation and the number is still rising. Despite the
keen interest shown by these molecules for many of them, the functional role in normal/
pathological condition is still unclear, additional studies are needed. Recently with the help of
the latest NGS techniques, new information is brought to light for better understanding
lncRNAs role, mechanisms of action, and also the potential use of them in various cancer
therapies.
Among the best well‐characterized lncRNAs are XIST (X inactive specific transcript) a 17‐kb‐
long transcript known for its role in dosage compensation involving X chromosome inactiva‐
tion and H19 transcript 2.5‐kb‐long that plays an important role in imprinting [244, 245].
Experimentally data sustain a potential oncogenic role for H19, an aberrant expression have
been identified in a variety of cancers: breast, ovarian, hepatocellular, gastric, lung, colon,
esophagus [246–251]. It has been shown that H19 oncogenic role is also due to the fact that the
transcript acts as a precursor for miARN‐675 leading to pRB gene expression decrease [252].
Another lncRNA having oncogenic potential is MALAT1 (metastasis‐associated lung adeno‐
carcinoma transcript 1) who it was suggested in many studies that can promote cell prolifer‐
ation apoptosis, invasion, and metastasis. Significantly high levels of MALAT1 expression
were detected in lung cancer, prostate cancer, colorectal cancer, hepatocellular carcinomas,
gynecologic (endometrial, cervical) cancer, osteosarcoma [253–262].
There are identified lncRNAs that appear to have tumor suppressor function in carcinogenesis.
For GAS5 (growth arrest specific 5) lncRNA, it was found to play an important role in apoptosis
induction; studies have reported a significantly reduced GAS5 levels of expression in breast
cancer and prostate cancer [263, 264]. Another report shows that GAS5 low level of expression
is associated with poor prognosis in hepatocellular carcinoma [265].
MEG3 (maternally expressed 3) is lncRNAs that presents a reduced expression in several types
of cancer. Several experimental evidences demonstrate that MEG3 interacts with p53 tumor
suppressor gene and regulates p53 target gene expression, therefore, inhibits tumor cell
proliferation and cancer progression. Aberrant levels of MEG3 expression have been identified
in glioblastoma, ovarian, colon, cervical, lung cancer [266–271].
In literature, there are a relatively small number of experimental data showing an association
regarding lncRNAs involvement in cervical carcinogenesis, but due to high interest shown
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toward these molecules the number is growing fast. The data collected so far on lncRNAs
involvement in cervical cancer are presented in Table 3.
LncRNA name Functions Expression pattern References
H19 (imprinted maternally expressed transcript) Located in an imprinted region near the insulin‐like
growth factor 2 (IGF2) gene. Potential dual role in
oncogenesis (tumor suppressor/oncogene)
Upregulated [275]
HOTAIR (HOX antisense intergenic RNA) Located within the Homeobox C (HOXC) gene locus is
co‐expressed with HOXC genes. Involved in HOXD
genes transcription repression via histones methylation
using PCR2 and LSD1 complex
Upregulated [276–279]
XIST (X inactive specific transcript) Role in X chromosome inactivation Upregulated [280]
MALAT1 (metastasis‐associated lung
adenocarcinoma transcript 1)
Regulates transcription of genes involved in cancer
metastasis cell migration, proliferation and cell cycle
regulation
Upregulated [281, 282]
ANRIL/CDKN2B‐AS1 (Antisense non‐coding
RNA in the INK4 Locus; CDKN2B antisense
RNA 1)
Located within the CDKN2B‐CDKN2A gene cluster;
interacts with PRC1 and PRC2 complexes for epigenetic
silencing of genes in this cluster
Upregulated [283, 284]
TUSC8 (tumour suppressor candidate 8;
XLOC_010588)
Unknown Downregulated [285]
BC200/BCYRN1 (brain cytoplasmic RNA 1) Encodes a neural small non‐messenger RNA Upregulated [286]
lncRNA‐EBIC (TMPOP2—thymopoietin
pseudogene 2)
Unknown Upregulated [287]
GAS5 (growth arrest specific 5) Promotes cellular growth arrest and apoptosis Downregulated [288]
MEG3 (maternally expressed gene 3) Inhibits tumor cell proliferation; a potential tumor
suppressor role due to p53 activation
Downregulated [269]
lincRNA‐p21 (TP53COR1—tumor protein p53
pathway corepressor 1)
Repress genes transcriptionally regulated by p53 Upregulated [283]
lncRNA‐LET (NPTN‐IT1—NPTN intronic
transcript 1)
Stabilizes nuclear factor 90 protein, promotes hypoxia Downregulated [289]
CCHE1 (CCEPR—cervical carcinoma expressed
PCNA regulatory lncRNA)
CCND1 ncRNA (cyclin D1 non‐coding RNA)
Regulates cyclin D1 gene expression Upregulated
Upregulated
[290]
[283]
SncmtRNA (Sense mitochondrial ncRNA)
ASncmtRNA (Antisense mitochondrial ncRNA
transcript)
Unknown ASncmtRNA
Downregulated
SncmtRNA‐2
(Upregulated)
[291]
Table 3. List of lncRNAs expressed in cervical cancer [272–274].
5. Epigenetic changes involved in viral gene expression
Methylation status of integrated HPV depends of viral life cycle as well as of neoplastic
transformation, this making HPV methylome a potential tool in cancer diagnostic. HPV
genome methylation status depends on the viral life cycle and is associated with neoplastic
progression.
According to Johanssen and Lambert study, viral genome is subjected to de novo methylation
by host DNMTs. Methylation of the viral genome may be a part of a mechanism involved in
innate response to pathogens by which the host attempts to suppress viral gene expression.
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The authors note that in HeLa cells, HPV18 genome chromatin histone modification status
correlates with the occupancy of host transcriptional machinery specifically within the LCR
[292]. E7 and E6 oncoproteins of hr‐HPVs appear to modulate host epigenetic machinery
through their interplay with both DNA methylation enzymes as well as chromatin remodeling
enzymes [159].
Mirabello et al. [293] reported in 2013 that they found 3‐region in L1 strongly methylated in
cancers and only in a small percentage in CIN I and CIN II lesions. In addition, the authors
shown that methylation at certain CpG sites can indicate an evolution toward CIN II+ years
before it happens.
Evaluation of cervical samples from HPV positive women, presenting precancerous lesions or
invasive ones, showing that the hypomethylation degree in LCR and E6 gene region increase
with the increasing of lesion severity. These data convinced the authors to conclude that
neoplastic transformation could be suppressed by hypermethylation, while hypomethylation
accompanies or leads to progression toward cancer [294].
Using laser microdissection on different layers from samples with HPV‐infected lesions,
Vinokurova and von Knebel Doeberitz [295] found dynamic changes in HPV16 LCR methyl‐
ation in the context of the viral life cycle. A decrease in methylation in the transcriptional
enhancer region within the LCR was observed in terminally differentiated epithelial compart‐
ment and meanwhile an increase in methylation within the region of the LCR containing the
early promoter was noted [295].
Another study highlighted heterogeneity of methylation status among patients, even in
samples from the same patient. Methylation frequency was found to be approximately 30% in
L1 region, less than in CpG islands around enhancer and promoter of HPV16. In most of the
HPV genome sites, hypermethylation is associated better with carcinoma than with dysplastic
lesions [296].
On the other hand, a study regarding methylation status in HPV18 immortalized cell lines
(HeLa and C4‐1) and in samples from patients, determined a clonally heterogeneity of
methylation status in different regions of viral genome. The clinical samples showed partial
or total methylation in HPV enhancer region, while in asymptomatic patient's, samples were
fully unmethylated. Viral promoter was reported to be methylated in tumor samples and in
cervical smears [297].
These studies indicate that methylation status of viral oncogenes in cervical lesions could be
the result of transcriptional activity level and not an event that leads toward neoplastic
progression. Further studies regarding the influence of DNA methylation on viral life cycle
focused on E2 (early gene involved in viral transcription and replication) gene methylation.
In vitro studies revealed that HPV16 URR (upstream regulatory region) methylation inhibit E2
protein capacity to bind DNA [298]. By looking at methylation status of E2BS (E2 binding sites)
in immortalized epithelial cells from a HPV16 positive patient, Kim et al. found this region to
be selectively hypomethylated in highly differentiated cell population, while heavily methy‐
lated in basal‐like differentiated cells. The conclusion was that methylation status of E2BS may
vary during the viral life cycle, this giving an insight on E2 modulation function during
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progression of infection [298]. E2BS is more frequently found in a hypermethylated state in
cervical lesions with extrachromosomal state of viral genome, while upon integration in the
host genome, it was found to be hypomethylated, except the cases in which viral genome
integrates as a concatemer, when only a small proportion are found hypomethylated and most
of them hypermethylated [292].
All this experimentally observations conclude that HPV genome methylation status could hold
a prognostic and progression value for cervical lesions.
6. Potential epigenetic biomarkers in cervical cancer
Cancer epigenome is currently in the researchers spotlight due to the fact that all the epigenetic
changes that accompany cervical carcinogenesis can be exploited as biomarkers. Thus, once
deciphered, the epigenetic peculiarities of cervical cancer might be used in the development
of new alternatives for screening or for the assessment of prognostic [299]. On the other hand,
the reversible nature of epigenetic alterations makes them attractive targets for new therapeu‐
tic approaches. Some of these discoveries have been proposed as investigation methods or
resulted in new treatment approaches and commercial tests [300]. By far, the most studied
epigenetic changes are the methylation patterns, especially the methylation markers of the
host. Abnormal methylation of promoters of tumor suppressor genes is common in different
type of cancers with the prospect of becoming a biomarker in oncology [301]. As the methyl‐
ation profile of these genes increases with the severity of cervical lesions, their status might be
used as potential biomarker for early detection of cervical cancer disease [302]. For a better
stratification of cervical cancer and precursor lesions, different specific methylation panels
have been suggested [303]. Using DMH (differential methylation hybridization) technique and
qPCR, Lai et al. [304] found in scrapings isolated from CIN3 lesions, a higher frequency of
methylation for SOX1, NKX6‐1, PAX1, WT1, and LMX1A genes. Siegel et al. [305] demon‐
strated that aberrant methylation levels of DAPK1, RARB, WIF1, and SLIT2 might increase
specificity to identify cervical cancer compared to viral testing alone. Also, the methylation
patterns of GGTLA4 (183 bp) and ZNF516 (241 bp) genes were proposed in a patent as
biomarkers for diagnosis of premalignant cervical lesions [306], while aberrant methylation of
PAX1, PTPRR, SOX1, and ZNF582 promoters were suggested as markers for AC screening
[307]. The studies that associate the methylation profile with cervical lesion severity have
resulted in a commercial test (GynTect) [308]. GynTect assay is based on methylation‐specific
PCR (MS‐PCR) and, if positive, detects specific methylated DNA sites in cervical smears.
Manufacturer recommend the test for cervical cancer screening, allowing the triage of women
over 30 years who tested positive for HPV. Moreover, GynTect may be performed using
residual material from the HPV test. So, this methylation assays might be use as a secondary
marker after HPV DNA testing in order to guide the subsequent clinical approach (referral to
colposcopy or initiating a certain therapy) [309].
Other authors correlated changes in host DNA methylation with the development of drug
resistance. Chen et al. [310] identified both genome‐wide and within individual loci changes
in an oxaliplatin‐resistant cervical cancer cell line derived from SiHa cell line. The methylation
of Casp8AP2 gene resulted in increased drug resistance in different cells.
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Masuda et al. [311] reported that aberrant methylation of Werner (WRN) gene that encode for
a DNA helicase, increased the sensitivity to CPT‐11 (an inhibitor of DNA topoisomerase I).
Iida et al. [312] reported aberrant hypermethylation of CHFR (checkpoint with forkhead and
ring finger) in adenocarcinoma and HeLa cell line (immortalized with HPV18) and correlated
this profile with lower sensitivity to anticancer therapy when compared to SSC, proposing this
pattern in adenocarcinoma as a potential biomarker for sensitivity to paclitaxel. Therefore, the
identification of methylation patterns associated with drug‐resistance might become a
valuable tool in cervical treatment with demethylation agents that can revert this epigenetic
change.
Regarding the methylation of viral DNA, data are still under debate. While some authors have
suggested that it is a defense mechanism of the host cell, others considered it is a way by which
the virus contributes to persistent infection. [313]. Other researchers considered that neoplastic
transformation may be suppressed by HPV CpG methylation, while demethylation occurs as
the cause of or concomitant with neoplastic progression [314]. Several authors proposed
HPV16 L1 ORF methylation as a predictive marker for CIN3+ [315] and elevated levels of CpG
6367 L1HPV16 methylation as marker to predict future CIN2+ in women older than 28 years
[293]. Also, Mirabello et al. [316] correlated elevated levels of CpG methylation in the L1, L2,
E2/E4 with CIN3 or worse and data were confirmed by other papers [317]. Moreover, Went‐
zensen et al. [317] found differential methylation patterns in CIN3 patients with multiple
infections thus suggesting a possible way to identify the causal type of HPV.
Cervical carcinogenesis is accompanied also by altered expression of methyltransferases. For
therapeutic purpose, Hamamoto et al. [318] had synthesized double‐stranded molecules that
inhibit the expression of SUV39H2 (suppressor of variegation 3–9 homolog 2) gene. This gene
encodes a HMT that methylate the H3K9 lysine residue and its hyperexpression correlates
with carcinogenesis. The silencing of CHFR through its promoter hypermethylation leads also
to the activation of DNA methyltransferases (including DNMT1). Different patterns of
demethylation obtained by silencing DNMT1 in experimental model (HeLa and SiHa cell lines)
indicate the inhibition of DNMT1 as a target for the treatment of cervical cancer with HPV18
infection [312]. These results showed that infection with different HPV genotypes differently
interfere with epigenetic mechanisms.
Molecular investigations of cervical tumors and cell lines immortalized with HPV have shown
that, from all ncRNA molecules, miRNAs profile is significantly changed when compared to
normal tissue, even in early stages of carcinogenesis [309]. Zheng et al. [319] provided data
that viral E6 and E7 oncoproteins deregulate the expression of several miRNAs via the E6‐p53
and E7‐pRb pathways. In turn, miRNAs may influence the expression of HPV genes by
targeting viral RNA transcripts, these recommended miRNAs as new biomarkers in cervical
screening. The panel of four circulating miRNAs (miR‐16‐2*, miR‐195, miR‐2861, miR‐49) [320]
are suggested as predictive biomarkers for the prognosis of cervical cancer patients, upregulate
expression of serum miR‐205 [321] and serum pattern of miR‐29a and miR‐200a may indicate
tumor histological grade and progression stage [322]. Li et al. [323] found lower levels of miR‐
218 levels in patients with high‐risk HPV comparing with control or those with low‐risk or
intermediate‐risk HPV. In Chinese population, Zhou et al. [324] reported a good correlation
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between a miR‐218 polymorphism and its target laminin 5B3 in cervical cancer invasiveness.
Epigenetic changes through methylation of miRNAs might correlate with cervical disease. A
panel of three miRs (miR‐149, miR‐203, and miR‐375) was found hypermethylated in HPV‐
positive cell lines [76] and miR‐203 and miR‐375 hypermethylation correlated with uterine
precancerous lesions [325].
miRNAs might be also used for cervical cancer therapy. On animal model, Liu et al. [227] who
noticed an inverse correlation between the expression of miR‐143 and Bcl2 suggested the
possibility of a therapeutic approach by targeting this pathway. Also, miRNAs might modulate
the sensitivity to chemotherapy. For example, miR‐375 might be a therapeutic target in
paclitaxel‐resistance of cervical cancer cells [326], while miR‐155 and miR‐281 increase
sensitivity to cisplatin [325]. Therefore, miRNA deregulation may become a target of the
investigations for evaluating the effectiveness of treatments in cervical cancer [327].
7. Conclusions
All these data underline the importance of epigenetic modification in tumor development and
cervical cancer risk assessment. Epigenetic alterations could be used as biomarkers for the
prognosis and evolution of the disease and for therapy response prediction. New techniques
in epigenetic investigations may yield better detection systems in order to identify new and
sensitive biomarkers that might contribute to improved screening assays, new therapeutic
approaches, and prediction biomarkers. The reversible nature of epigenetic alterations
provides new opportunities in the development of therapeutic agents targeting epigenetic
modification in oncogenesis.
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